Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Vis graf over relationer

Primære forskningsområder

Curriculum vitae

 

Name: Steen Andersen

 

Title:
Chief physician, DMSc

Current position:
Chief Consultant, DMSc (Endocrinology), Department of Cardiology, Nephrology and Endocrinology, Nordsjællands Hospital (2012)

PhD Associate Professor at University of Copenhagen (2013)

Education:

MD (1990), certified specialist in internal medicine/endocrinology (2008), DMSc (2008)



Research experience and research interest:
Diabetes with particular emphasis on late diabetes complications and in recent years even diabetes technology.

Clinical studies of the renin-angiotensin-aldosterone system (RAAS) in hypertensive patients with diabetic nephropathy has focused on clarifying pathophysiological mechanisms and effects of RAAS blockade, particularly the effect of blockade of the angiotensin 2 subtype-1 receptor (ARB) and inhibition of aldosterone on the progression of diabetic nephropathy. An important finding is that the renoprotective effect of ARB seems to be at level of Angiotensin-Converting-Enzyme (ACE) – Inhibition achieved by changing glomerular permeability.

 

Prevention of progression of nephropathy through optimization of glycemic control and reduction of glycemic variability is now being investigated in studies of patients with type 1 diabetes treated with insulin pump compared to multiple daily injections. Preliminary observational study suggests a renoprotective effect of insulin pump as evaluated by reduced albuminuria. A clinical trial is ongoing in which participants are randomly assigned to insulin pump with continuous glucose monitoring or insulin pen.

Investigator or co-investigator in 5 international multicentre RCT.

Mentor and supervision of graduate and postgraduate students:
Main supervisor of 1 PhD student and 1 bachelor thesis. Reviewer of 1 PhD thesis.

Peer review:
Acta Endocrinol, Diabetes Care, Diabetologia,, J Diab Sci Technol, Nephrology, Dialysis Transplantation

Publications:
25 scientific articles, 1 multicentertudie, 2 scientific letters, 2 review, 82 abstracts.

Selected scientific original articles:


• S Andersen, Blouch K, J Bialek, Deckert M, Parving HH, Myers BD. Glomerular permselectivity in early stages of overt diabetic nephropathy. Kidney Int 2000; 58 (5): 2129-2137.
• Andersen S, Tarnow L, Rossing P, Hansen BV, Parving HH. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int 2000; 57: 601-606.
• Andersen S, Rossing P, Juhl TR, Deinum J, Parving HH. Optimal dose of losartan for renoprotection in diabetic nephropathy. Nephrol Dial Transplant 2002; 17 (8): 1413-1418.
• Andersen S, Jacobsen P, Tarnow L Rossing P, Parving HH. Time course of the antiproteinuric and antihypertensive effects of losartan in diabetic nephropathy. Nephrology Dialysis Transplantation 2003; 18: 293-297.
• Andersen S, Tarnow L, Cambien F, Rossing P, Juhl TR, Deinum J et al. Renoprotective effects of losartan in diabetic nephropathy: Interaction with ACE insertion / deletion genotype? Kidney Int 2002; 62 (1): 192-198.
• Parving HH, Lehnert H, Brøchner-Mortensen J, Gomis R, Andersen S and Arner P .: The effect of Irbesartan on development of diabetic nephropathy in patients with type 2 diabetes
New England Journal of Medicine, Vol. 345 (12) pp. 870-878 (2001) September 20
• Andersen S, Tarnow L, Cambien F, Rossing P, Juhl TR, Deinum J et al. Long-term renoprotective effects of losartan in diabetic nephropathy: Interaction with ACE insertion / deletion genotype? Diabetes Care. 2003 May; 26 (5): 1501-6.
• Jacobsen P, Andersen S, Rossing K, Jensen BR, Parving HH. Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy.
Kidney Int. 2003 May; 63 (5): 1874-80
• Andersen S, Brochner-Mortensen J, Parving HH: Kidney function during and after withdrawal as of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria.
Diabetes Care. 2003 Dec; 26 (12): 3296-302.
• Jacobsen P, Andersen S, Jensen BR, Parving HH. Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy.
J Am Soc Nephrol. 2003 April; 14 (4): 992-9.
• Schøjdt, KJ, Andersen S, Rossing P, Tarnow L, Parving HH. Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is Associated with enhanced decline in glomerular filtration rate. Diabetologia. 2004 Nov; 47 (11): 1936-9
• Andersen S, AV Nieuwenhoven F, Tarnow L, Rossing P, Rossing K, Parving HH. Reduction of urinary Connective Tissue Growth Factor by Losartan in hypertensive type 1 diabetic patients with diabetic nephropathy. Kidney Int. 2005 June; 67 (6): 2325-29.
• Schjødt KJ, Lajer M, Andersen S, Tarnow L, Rossing P, Parving HH. Aldosterone synthase (CYP11B2) -344T / C polymorphism and renoprotective besvarelse losartan treatment in diabetic nephropathy.
Scand J Clin Lab Invest. 2006; 66 (3): 173-80.
• Nguyen TQ, Tarnow L, Andersen S, Hovind P, Parving HH, Goldschmeding R, van Nieuwenhoven FA.Urinary connective tissue growth factor excretion correlates with clinical markers of renal disease in a large population of type 1 diabetic patients with diabetic nephropathy.
Diabetes Care. 2006 Jan; 29 (1): 83-8.
• Lajer M, Tarnow L, Andersen S, Parving HH: CYP2C9 variant MODIFIES blood pressure-Lowering besvarelse Losartan in Type 1 diabetic patients with nephropathy.
Diabet Med. 2007 March; 24 (3): 323-5
• Andersen S, Mischak H, Zürbig P, Parving HH, Rossing P. Urinary proteome analysis Enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria. BMC Nephrol. 2010 Nov 1; 11: 29
• Nielsen SE, Andersen S, Zdunek D, Hess G, Parving HH, Rossing P. Tubular markers do not predict the decline in glomerular filtration rate in type 1 diabetic patients with overt nephropathy. Kidney Int. 2011 May; 79 (10): 1113-8
• Rosenlund S, Theilade S, Hansen TW, Andersen S, Rossing P Insulin pump treatment is Associated with Decreased arterial stiffness. Acta Diabetologica 2014 December 51 (6) 955-62

 

 

                                                                                       Steen Andersen/ December 2014

ID: 44814553